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Combined transcriptome studies identify AFF3 as a mediator
of the oncogenic effects of β-catenin in adrenocortical
carcinoma
L Lefèvre1,2,3, H Omeiri1,2,3,13, L Drougat1,2,3,13, C Hantel4, M Giraud1,2,3, P Val5,6,7, S Rodriguez1,2,3, K Perlemoine1,2,3, C Blugeon8,9,10,
F Beuschlein4, A de Reyniès11, M Rizk-Rabin1,2,3, J Bertherat1,2,3,12 and B Ragazzon1,2,3
Adrenocortical cancer (ACC) is a very aggressive tumor, and genomics studies demonstrate that the most frequent alterations of
driver genes in these cancers activate the Wnt/β-catenin signaling pathway. However, the adrenal-speciﬁc targets of oncogenic
β-catenin-mediating tumorigenesis have not being established. A combined transcriptomic analysis from two series of human
tumors and the human ACC cell line H295R harboring a spontaneous β-catenin activating mutation was done to identify the
Wnt/β-catenin targets. Seven genes were consistently identiﬁed in the three studies. Among these genes, we found that AFF3
mediates the oncogenic effects of β-catenin in ACC. The Wnt response element site located at nucleotide position − 1408 of the
AFF3 transcriptional start sites (TSS) mediates the regulation by the Wnt/β-catenin signaling pathway. AFF3 silencing decreases cell
proliferation and increases apoptosis in the ACC cell line H295R. AFF3 is located in nuclear speckles, which play an important role in
RNA splicing. AFF3 overexpression in adrenocortical cells interferes with the organization and/or biogenesis of these nuclear
speckles and alters the distribution of CDK9 and cyclin T1 such that they accumulate at the sites of AFF3/speckles. We demonstrate
that AFF3 is a new target of Wnt/β-catenin pathway involved in ACC, acting on transcription and RNA splicing.
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INTRODUCTION
Adrenocortical cancer (ACC) is a very aggressive tumor with a
5-year survival rate below 35% in most series.1 There are few
effective treatments available.2 At present, surgery is the only
curative therapy available and is only effective if complete tumor
removal is possible. In progressive patients, medical therapy is of
very limited efﬁcacy. Several studies show the importance of the
Wnt/β-catenin signaling pathway in the development and
maintenance of numerous organs, and that alterations of the
Wnt/β-catenin signaling are involved in a wide range of human
diseases, and especially malignancies.3–6
The Wnt/β-catenin pathway is required for normal adrenal (NA)
gland formation, and adrenocortical cell-speciﬁc knockout of
Ctnnb1 in mice results in adrenal gland aplasia.7 Gene alterations
leading to a constitutive activation of this pathway are the
most frequent events in ACC.8 Constitutive activation of the
Wnt/β-catenin pathway in the adrenal cortex of transgenic
mice leads to the development of adrenocortical tumors with
malignant characteristics.9,10 Inhibition of the Wnt/β-catenin
pathway in the adrenocortical cell line H295R by PKF115-584 or
a shRNA against β-catenin messenger RNA (mRNA) increases
apoptosis11,12 and is associated with a complete absence of tumor
growth in a xenograft model.12
These observations implicate alterations of Wnt/β-catenin in
ACC pathogenesis. Few Wnt/β-catenin target genes, including the
canonical target AXIN2, have been shown to be upregulated in
ACC,13 but there has been no comprehensive and integrative
study to identify all speciﬁc Wnt/β-catenin targets in ACC.
A better understanding of the biological processes affected by
Wnt/β-catenin pathway alterations in ACC may allow the
identiﬁcation of therapeutic targets and thereby contribute to
the development of new therapeutic strategies. The aim of this
study was to use a combination of transcriptome analysis and
cellular experiments to identify the targets of the Wnt/β-catenin
pathway involved in adrenocortical tumorigenesis.
RESULTS
Identiﬁcation of Wnt/β-catenin targets in ACC
We performed a combined transcriptomic analysis on cohorts of
ACC and on human cell models to identify alterations of gene
expression due to aberrant Wnt/β-catenin pathway activation.
Two independent ACC microarray data sets8,10 were analyzed
for genes whose expression is correlated with the common
Wnt/β-catenin pathway target gene, AXIN2 (Supplementary
Figure S1-A and Supplementary Table S1); combining results of
the two cohorts, 21 mRNAs were positively correlated (adjust
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P-valueo0.05 and Pearson's r40.6 in both cohorts) and 1 mRNA
was negatively correlated (adjust P-valueo0.05 and Pearson's
ro − 0.6 in both cohorts) (Figure 1a).
We used the H295R cell line, human adrenocortical cells,
harboring a heterozygous CTNNB1 (β-catenin) gene mutation
affecting the GSK3β phosphorylation site (S45P) and leading to
constitutive transcriptional activity of β-catenin-lymphoid enhan-
cer binding factor (LEF)/T-cell factor (TCF). Whole-transcript gene
expression was analyzed in three stable clones of H295R cells
expressing a doxycyclin-inducible small hairpin RNA (shRNA)-
targeting CTNNB1 mRNA (shβ).12 We established a list of genes
showing similar expression proﬁles in the three clones after
CTNNB1 silencing. A control clone was used to eliminate from this
list those genes whose expression was sensitive to doxycyclin
treatment. We thereby identiﬁed 44 genes signiﬁcantly
downregulated (adjusted P-valueo0.05 and log2 ratioo − 1)
and 29 genes signiﬁcantly upregulated (adjusted P-valueo0.05
and log2 ratio41) by speciﬁc CTNNB1 inactivation (Figure 1b,
Supplementary Figure S1-B and Supplementary Table S1).
We further studied only the genes common to the two lists.
In addition to AXIN2, there were six genes positively associated
in both experiments with Wnt/β-catenin pathway activation:
lymphoid enhancer binding factor 1 (LEF1); AF4/FMR2 family,
member 3 (AFF3); family with sequence similarity 19 (chemokine
(C–C motif)-like), member A4 (FAM19A4); isthmin 1; angiogenesis
inhibitor (ISM1), acid phosphatase-like 2 (ACPL2); and naked cuticle
homolog 1 (Drosophila) (NKD1) (Figure 1, black circles, 2a and
Supplementary Table S1). Two of these genes are already known
to be transcriptional targets of the Wnt/β-catenin pathway; one,
NKD1, acts as a negative feedback regulator, and the other, LEF1,
mediates, with β-catenin, a nuclear response.
We validated the Wnt/β-catenin pathway-dependent expres-
sion of all these six genes by real time-PCR in H295R-shβ cells
in parental H295R cells transiently transfected with a small
interfering RNA construct targeting another region of the CTNNB1
mRNA, and in established tumors with CTNNB1 inactivation
from a subcutaneous xenograft model (Figures 2b and c and
Supplementary Figure S2-A and B).
CTNNB1 (β-catenin) silencing in adrenocortical cells H295R leads
to increased apoptosis (reference 12 and Figure 3). We therefore
investigated if silencing of the potential β-catenin target genes
mimicked this effect on apoptosis. LEF1 silencing had similar
effects to CTNNB1 silencing on apoptosis, as expected since LEF1
is involved in nuclear response of Wnt/β-catenin pathway. Of the
other genes (AFF3, FAM19A4, ISM1, ACPL2, AXIN2 and NKD1), AFF3
silencing had the largest effect on apoptosis (Figure 3 and
Supplementary Figure S2-C). We therefore focused our analysis
on AFF3 and investigated its role, if any, in adrenocortical
oncogenesis.
AFF3, a new Wnt/β-catenin target
The dysregulation of Wnt/β-catenin pathways allows β-catenin to
accumulate and translocate to the nucleus, where it may activate
the transcription of target genes. This nuclear accumulation can
be detected by immunohistochemistry. AFF3 was more abundant
in ACC positive for nuclear β-catenin staining (βcat+) than in ACC
without such nuclear staining (βcat− ) and in NA in both cohorts
(Figure 4a). AFF3 is not more strongly expressed in NA than in
other tissues (Supplementary Figure S3). AFF3 expression was
signiﬁcantly associated with a poor overall survival in the
two cohorts of ACC, whether analyzed as a continuous variable
(cohort 1: P= 0.00927, hazard ratio = 1.68, 95% conﬁdence
interval = 1.12–2.51; cohort 2: P= 0.00649, hazard ratio = 2.2, 95%
conﬁdence interval = 1.19–4.09) or after dichotomization between
ACC with low and high AFF3 expression (Figure 4b).
Wnt/β-catenin regulation of gene expression generally involves
binding of LEF/TCF transcription factors to Wnt response elements
(WREs) and recruitment of the activator β-catenin. The AFF3 gene
consists of 23 coding exons and two 5′ non-coding exons,
with two major transcriptional start sites (TSS).14 To assess the
transcriptional activity of AFF3 in human adrenal cells, we mapped
transcriptome sequencing reads with mRNA (RNA-seq) from
H295R cells and we examined the regions surrounding the two
putative TSSs (Figure 5a). There was no transcription of exons 1 or
2 in the RNA-seq from H295R, whereas there were high levels of
exon 3 reads; these ﬁndings suggest that only the TSS located at
the beginning of exon 3 is used in adrenocortical cells. Analysis of
the AFF3 promoter region from positions –1500 to +500 bp
from this TSS revealed one putative WRE (Figure 5a). In H295R
cells, ΔN-TCF4, an inhibitor of β-catenin/TCF, decreased the
transcriptional activity of the β-catenin-LEF/TCF-dependent
luciferase reporter construct top-ﬂash and decreased AFF3 mRNA
levels, similarly to AXIN2 (Figure 5b). LEF1 silencing had a similar
effect and led to decreases AFF3 mRNA levels (Figure 5b).
Two copies of the putative AFF3 WRE (wild type or mutant)
Figure 1. Identiﬁcation of Wnt/βcatenin target genes in adrenocortical cancer. (a) To identify gene's expression that is closely correlated with
AXIN2 expression and that might also be Wnt/β-catenin targets, we performed Pearson's r correlation tests with expression data sets from two
independent cohorts of ACC (cohort 18 and cohort 210). Each dot in left panels represents the Pearson correlation coefﬁcient (r) for each gene
in the two cohorts (detailed in ﬁgure S01-A and Supplementary Table S1). The genes best correlated with AXIN2 are represented in red
(positively; r40.6 in both cohorts) or blue (negatively; ro–0.6 in both cohorts). (b) The volcano plot in the right panels shows the differential
expression of genes in three stable clones of the human adrenocortical cell line H295R, which carries a construct encoding a doxycyclin-
inducible shRNA targeting CTNNB1 mRNA (shβ). Dots in gray represent genes that did not show signiﬁcant changes in expression, dots in red
on the left indicate the genes with signiﬁcantly downregulated expression (adjust P-valueo0.05 and log2 ratioo–1) and dots in blue on the
right indicate the genes with signiﬁcantly upregulated expression (adjust P-valueo0.05 and log2 ratio41). Black circles represent the genes
common to both analyses.
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were inserted in tandem into the reporter plasmid, pGL3Tk,
where luciferase expression is driven by the minimal Tk promoter
(2xWT or 2xMut). In transfected cells the transcriptional activity
of the reporter construct (2xWT) was higher than that of the
mutated construct (2xMut) (Figure 5b, shβ-MUT-Luc 0.5 ± 0.07 vs
shβ-WT-Luc: 1 ± 0.3, Po0.01). The transcriptional activity of the
2xWT was lower (0.4 ± 0.07, Po0.01) in H295R cells expressing a
shRNA-β-catenin (shβ with dox). Doxycyclin treatment did not
affect activity of the 2xMut construct with mutated LEF/TCF sites.
These results are consistent with the proﬁles of the canonical
reporter constructs TOP/FOP-Flash (Figure 5b).
Two nuclear protein isoforms can be produced from the AFF3
gene, and differ owing to the alternative splicing of exon 4
without frameshift. PCR analysis of cDNA using oligonucleotides
corresponding to parts of exon 3 and exon 5 showed that the
mRNA for isoform 1 (v1), without exon 4 (NP_002276.2, 1226
amino acid), was the most abundant of the two mRNAs in
adrenocortical cells (Figure 5a). Consistent with this result, only
one protein was detected in nuclear protein extracts of
adrenocortical cells, and its abundance was β-catenin-dependent
(Figure 5c, siCTNNB1 vs siCtr).
AFF3 silencing alters apoptosis and proliferation
Adrenocortical cell lines carrying constructs encoding a doxycylin-
inducible shRNA targeting AFF3 were generated (shAFF3). Five
days following shRNA-AFF3 induction by doxycyclin (dox) treat-
ment, AFF3 mRNA and protein levels were signiﬁcantly decreased
(Figure 6a). In contrast, doxycyclin treatment had no effect on
AFF3 expression in control lines (Ctr) (Figure 6a). AFF3 silencing
by shRNA (+dox) increased the apoptosis rate and increased
caspase activity (Figure 6b), a result that agrees with the ﬁndings
of the transient knockdown experiment (Figure 3). Likewise,
AFF3 silencing increased the apoptotic effect of staurosporin
(staurosporin had no signiﬁcant effect on controls). The effect of
AFF3 silencing on H295R cell proliferation was measured by MTT
(3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) and
Figure 2. β-catenin-dependent genes expression in adrenocortical carcinoma and cell lines. (a) Pearson correlation between log2 values of
AXIN2 expression and expression of genes identiﬁed in Figure 1 (LEF1, AFF3, FAM19A4, ISM1, ACPL2, AXIN2 and NKD1) in both cohorts of ACC.
Each dot represents ACC without (white) or with (black) Wnt/β-catenin pathway activation. (b) Histograms represent levels of the mRNAs of
LEF1, AFF3, FAM19A4, ISM1, ACPL2, AXIN2 and NKD1 in Ctr and shβ clones 2, 5 and 10 days after addition of doxycyclin (dox, 0.2 mg/ml) to the
culture medium and (c) in parental H295R cells after transient transfection with siCtr or siβcat.
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colony-formation assays: silencing signiﬁcantly decreased prolif-
eration (−75% at 16 days, Po0.001, Figure 6c) and reduced the
rate of colony formation (Figure 6d), with respect to the shAFF3
cell line without AFF3 silencing (–dox) or the control line.
AFF3 alters nuclear speckles and interacts with P-TEFb
AFF (AF4/FMR2) proteins have been found in nuclear speckles,15
which serve as a reservoir of factors participating in mRNA
splicing. AFF (AF4/FMR2) proteins have been also described in the
super elongation complex (SEC), which contains the positive
transcription elongation factor b (P-TEFb) and other elongation
factors,16 and positively regulates transcriptional elongation by
the RNA polymerase II. In adrenocortical cells, AFF3 colocalized
with the SC35 protein (a nuclear speckle marker) (Figure 7a, line 1).
Strong overproduction of AFF3 altered the nuclear distribution of
SC35 protein (Figure 7a, line 2) although the overproduction of
another speckle component (acinus) had no effect on the
distribution of SC35 (Supplementary Figure S4). To determine
whether AFF3 is present in SEC in adrenocortical cells, AFF3 was
Figure 3. Genes silencing and apoptosis. Apoptosis was analyzed by quantiﬁcation of cleaved caspase-3 level (a and b) and caspase-3/7
activity (c and d) in H295R cells after gene silencing for 5 days without (a and c) and with staurosporin (b and d) for the 6 last hours (50 ng/ml).
Histograms in a an b represent the quantiﬁcation of cleaved caspase-3 proteins from one experiment representative of three independent
experiments. Histograms in c and d represent caspase-3/7 activity from three independent experiments.
Figure 4. AFF3 expression in ACC. (a) Boxplots representing the expression level of AFF3 in ACC positive for nuclear β-catenin staining (βcat+, in
red) compared with ACC negative for such nuclear staining (βcat–, blue) and in normal adrenal tissue (NA, in green) from two independent
expression data sets (cohort 18 and cohort 210). (b) The Kaplan–Meier estimates of overall survival of patients with ACC according to AFF3
expression. The P-value of the log-rank test for differences between survival curves is shown. Below, ACC are ordered by their AFF3 expression
value centered on the cutoff value and the speciﬁc death is indicated by black rectangles.
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Figure 5. AFF3 is a β-catenin target gene in adrenocortical carcinoma cells. (a) Genomic structure of the AFF3 gene with the two putative
transcription start sites (TSS) at the beginning of exons 1 and 3 indicated by two arrows. Each black rectangle represents an exon. Y axis values
show the read depth of RNA-seq analysis on adrenocortical cells H295R. Finer details of the AFF3 TSS regions are shown and demonstrate that
only the TSS at exon 3 is used. Promoter analysis (nucleotide positions –1500 to +500) by Genomatix software identiﬁed one Wnt Response
Element (WRE) shown in the lower left box. The AFF3 variant mRNAs produced were analyzed by producing cDNA from total mRNA from
H295R cells, then PCR using oligonucleotides corresponding to sequences in exon 3 and exon 5, followed by agarose gel electrophoresis;
167 bp: isoform 1 and 242 bp: isoform 2. (b) The upper histograms represent the effects in H295R cells of ΔN-TCF4 (an inhibitor of the
β-catenin/TCF pathway) and LEF1 silencing on the β-catenin-LEF/TCF-dependent luciferase reporter construct Top-ﬂash (left panel) and
expression of other genes as indicated (right panel). The lower histograms represent the effects of β-catenin silencing by dox treatment of the
shβ line on the expression of Top-Flash and luciferase constructs, with two copies of the putative AFF3 WRE wild-type sequence (2xWT) or
mutant sequence (2xMut). (c) Western blot analysis of AFF3 protein accumulation in H295R cells (cytosol/nucleus) after CTNNB1 (siCTNNB1) or
AFF3 (siAFF3-1 and 2) silencing. Histograms represent the quantiﬁcation of AFF3 proteins from one experiment representative of three
independent experiments.
Figure 6. AFF3 silencing alters apoptosis, proliferation and colony forming. (a) Histogram of AFF3 mRNA levels and western blotting showing
protein accumulation in Ctr and shAFF3 clones 5 days after addition of doxycyclin (dox) to the culture medium (0.2 mg/ml). (b) In the
apoptosis illustration, histograms represent caspase-3/7 activity, after vehicle or dox treatment for 5 days, without or with staurosporin
co-treatment for the last 6 h (50 ng/ml). (c) Cell survival, reported in graph labeled proliferation, was assessed by the MTT assay without or with
dox (0.2 mg/ml) treatment for 1, 6, 12 or 16 days. (d) Colony formation by Ctr and shAFF3 clones without or with dox (0.2 mg/ml) treatment for
30 days was visualized by crystal-violet staining.
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immunoprecipitated from nuclear extracts. CDK9 and cyclin T1,
both components of P-TEFb, co-immunoprecipitated with AFF3
(Figure 7b, top). The interactions were conﬁrmed by reciprocal co-
IP of endogenous CDK9 and overproduced AFF3-ﬂag (Figure 7b,
middle) or endogenous AFF3 (Figure 7b, bottom). CDK9 and cyclin
T1 were present in the nucleus where spots of high concentration
were observed; these spots colocalized with SC35 (Figure 7a,
lines 3 and 4). AFF3 overproduction altered the nuclear distribu-
tion of CDK9 and cyclin T1, and seemed to concentrate them at
the sites of AFF3 accumulation (Figure 7a, lines 5 and 6),
consistent with immunoprecipitation results. Similar results were
obtained in HeLa cells (data not shown).
DISCUSSION
In many cancers, the Wnt/β-catenin signaling pathway has an
important role in regulating cell growth, motility and
differentiation.6,17 We and others have demonstrated the
importance of the Wnt/β-catenin signaling pathway activation
in adrenal cortex tumorigenesis.9,10,13,18–23 Using combined
transcriptomic analysis we have identiﬁed new target genes of
the Wnt/β-catenin signaling pathway. We show that one of these
genes, AFF3, mediates some of the effects of Wnt/β-catenin
signaling pathway activation in ACC (Figure 8). We have identiﬁed
the AFF3 TSS used in adrenocortical cells at the beginning of
exon 3. This predominantly produces a mature mRNA devoid of
exon 4, which encodes isoform 1 of the AFF3 protein (1226 amino
acid). We also report that the WRE site located at nucleotide
position –1408 of the AFF3 TSS, mediates the regulation by the
Wnt/β-catenin signaling pathway.
The AFF (AF4/FMR2) family of genes includes four members:
AFF1 (or AF4, acute lymphoblastic leukemia-1 fused gene from
chromosome 4), AFF2 (or FMR2, Fragile X mental retardation 2),
AFF3 and AFF4 (or AF5Q31, acute lymphoblastic leukemia-fused
gene from 5q31). AFF2 is silenced in cases of Fragile XE (FRAXE)
intellectual disability. Proteins encoded by AFF1, AFF3 and AFF4
are produced as fusions with that encoded by MLL in acute
lymphoblastic leukemia patients.24–26 In the mouse, Aff3 shows
Figure 7. AFF3 overexpression alters nuclear speckles and pTEFb. (a) Lines 1 and 2: H295R cells were transfected with AFF3-Flag vector. The
AFF3 protein was revealed with an anti-Flag antibody and nuclear speckles were detected using an anti-SC35 antibody. After 8 h of expression
of the vector, AFF3 colocalized with SC35 in nuclear speckles; after 24 h, the distribution of SC35 was altered. Lines 3 and 4: CDK9 and cyclin T1
protein were detected using anti-CDK9 and anti-cyclin T1 antibodies. In H295R cells, CDK9 and cyclin T1 colocalized with SC35 in nuclear
speckles. Lines 5 and 6: H295R cells were transfected with AFF3-Flag vector. AFF3 overproduction resulted in CDK9 and cyclin T1 being found
colocalized with AFF3. The white dashed rectangle in the merge column represents the enlarged area used for colocalization analysis using
ImageJ software. Pearson's colocalization coefﬁcients (PCC) were determined with JACoP plugin49 in cells from different experiments (n⩾ 10).
t-test was used to evaluate the difference between PCC for AFF3/SC35 colocalization analysis after 8 and 24 h of transfection (lines 1 and 2).
(b) Protein lysates from H295R cells overexpressing AFF3-Flag or Ctr vectors were immunoprecipitated with Anti-Flag M2 Afﬁnity Gel and
analyzed by western blot using the indicated antibodies. Overproduced AFF3 associated with CDK9 and Cyclin T1. Protein lysates from H295R
cells overexpressing AFF3-Flag or silenced for AFF3 by siAFF3 were immunoprecipitated with anti-CDK9 antibodies and analyzed by western
blot using the indicated antibodies. CDK9 associated with overproduced and endogenous AFF3. AFF3 silencing in H295R cells conﬁrmed the
speciﬁcity of the protein band of endogenous AFF3.
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strong regional expression in the developing brain, somites and
limb buds.14,27–29 This expression pattern is consistent with
mesomelic dysplasia and central nervous system abnormalities
observed in a female infant with a microdeletion on chromosome
2, only affecting the AFF3 gene.28 A recent study identiﬁed a CGG
repeat expansion, associated with intellectual disability, in the
promoter of AFF3 at an autosomal folate-sensitive fragile site
named FRA2A.14 This polymorphic repeat is hypermethylated in
FRA2A, leading to silencing of AFF3 in the nervous system.14 Aff3 is
expressed in the mouse adrenal cortex during embryonic
development (E14.5) and thus may be implicated in adrenal
development (Supplementary Figure S5). AFF3 has been identiﬁed
as a novel susceptibility locus for several autoimmune diseases,
notably rheumatoid arthritis,30–33 type I diabetes34,35 and Graves'
disease.36 AFF3 has been found to be abnormally expressed in
~ 20% of breast cancers, suggesting that it may act as a proto-
oncogene.37 A gene set enrichment analysis of several expression
data sets from breast cancers shows a link between genes
correlated to AFF3 expression and the Wnt/β-catenin pathway
(Supplementary Figure S6-A). Moreover, AFF3 expression is
positively correlated with CCND1 expression (Supplementary
Figure S6-B), which is a direct target of the Wnt/β-catenin
pathway in breast cancer cells.38 These observations suggest that
AFF3 expression is Wnt/β-catenin-dependent in breast cancers as
it is in ACC.
In H295R adrenocortical cells, AFF3 is located in nuclear
speckles; its overproduction interferes with the organization
and/or biogenesis of these nuclear speckles, conﬁrming previous
ﬁndings in HeLa cells.15 Several lines of evidence point to speckles
being storage/assembly/modiﬁcation compartments that supply
splicing factors to active transcription sites.39 CDK9 and cyclin T1,
two major components of P-TEFb involved in transcriptional
elongation via phosphorylation of the RNA polymerase II, are
diffusely distributed throughout the nucleoplasm with an overlap
with nuclear speckles.39 We report that in H295R adrenocortical
cells, AFF3 interacts with CDK9 and cyclin T1, and its over-
production alters the nuclear distribution of these two proteins
such that they accumulate at the sites of AFF3/speckles. AFF3 and
P-TEFb form the SEC-like 3 recently described in HEK293 cells.16
The SEC consists of the RNA polymerase II elongation factors
eleven-nineteen Lys-rich leukemia (ELL) proteins, EAF1/2 (ELL-
associated factor) proteins, P-TEFb and several frequent myeloid/
lymphoid or mixed-lineage leukemia translocation partners, such
as AF9, ENL, AFF1, AFF4 and AFF3. It is one of the most active
P-TEFb-containing complexes and is required for rapid induction
of transcription by paused RNA polymerase II. The signiﬁcant
overlap of genes downregulated by AFF3 silencing with genes
controlled by CDK9 (determined by inhibition of CDK9 by
Flavopiridol40) suggests that AFF3 modulates P-TEFb activity in
adrenocortical cells (Supplementary Figure S6–C).
Two recently developed inhibitors (JQ1 and I-BET151) of
bromodomain and extraterminal family members block cell
proliferation of leukemia cell lines. They do so by indirectly
interfering with the recruitment of SEC to chromatin from key
cancer-related genes such as v-myc avian myelocytomatosis
viral oncogene homolog (MYC), B-cell lymphoma 2 (BCL2) and
Figure 8. Target genes of the Wnt/β-catenin pathway in adrenocortical carcinoma. In the absence of Wnt factors, β-catenin is phosphorylated
by GSK3β and CK1α as part of a multiprotein complex. Phosphorylated β-catenin is then degraded by proteasomes. In the presence of Wnt
factors, Wnt binds to its frizzed receptor inhibiting the degradation complex that leads to cytoplasmic accumulation of β-catenin. Then,
β-catenin migrates to the nucleus and associates with the LEF/TCF transcription factor to induce transcription of speciﬁc target genes. The
CTNNB1 mutation leads to a constitutive transcriptional activity of β-catenin-LEF/TCF. Here, we have identiﬁed candidate genes regulated by
the Wnt/β-catenin pathway in adrenocortical carcinoma. Among these genes, we identiﬁed AFF3 as a direct target of the Wnt/β-catenin
pathway. AFF3 is localized in nuclear speckles and is associated with P-TEFb. AFF3 may have a role in adrenocortical tumorigenesis by acting
on transcription and RNA splicing. Two genes may regulate the Wnt/β-catenin pathway: LEF1 may participate in transcriptional activation and
NKD1 has been described as negative regulator. It might be also interesting to study the roles, if any, of FAM19A4, ACPL2 and ISM1 in
adrenocortical tumorigenesis.
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cyclin-dependent kinase 6 (CDK6).41–43 It would therefore be
worth pursuing the development of inhibitors that more
directly interfere with the organization or stability of the SEC.
Such inhibitors would be potential anticancer drugs for use
against ACCs and other cancers, such as breast cancer, with
overexpression of SEC components and in particular members of
the AFF family.
MATERIALS AND METHODS
Cell culture, generation of clones and cells transfection
ACC cells (H295R, ATCC CRL-2128) and HeLa cells (ATCC CCL-2) were
cultured, transfected and stimulated with staurosporin as previously
described.12,44–46 H295R stably transfected with the Tet repressor (H295R/
TR) was kindly provided by Dr Lalli.47 H295R/TR/shRNA-βcatenin (shβ)
clones carrying constructs encoding doxycyclin-inducible shRNAs targeting
either CTNNB1 (βcatenin) are described in.12 The pSuperior.puro vector
(Oligoengine), which can expresses a doxycyclin-inducible shRNA, was
used to created the H295R/TR/shRNA-AFF3 clones. Silencing hairpin
targeted AFF3 mRNA (targeted sequence: 5′-TAAGGACTCTCAGCTTGTA-3′)
was cloned into pSuperior.puro vector following the manufacturer’s
instructions to give ﬁnally the pSuperior.puro/shRNA-AFF3 vector. H295R/
TR cells were further transfected with the pSUPERIOR.puro/shRNA-AFF3
vector and clones were selected with puromycin (5 μg/ml, Sigma-Aldrich
P9620, Saint-Quentin Fallavier, France). Three shRNA-AFF3 clones (shAFF3
clones) were selected in which AFF3 expression was downregulated at
least 0.5-fold in a doxycyclin (0.2 mg/ml, Sigma)-dependent manner in
comparison with control clone (Ctr) transfected with pSuperior.puro vector.
All cell clones were investigated for their ability to express speciﬁc
adrenocortical genes (StAR and CYP11B1). S45P CTNNB1 (β-catenin) gene
activating mutation, previously identiﬁed in the parental H295R cell line,
was conﬁrmed by direct sequencing in all Ctr and shAFF3 clones (data not
shown). The data presented are from a single Ctr clone and a single shRNA
clone, but all results from in vitro experiments were conﬁrmed by similar
ﬁndings with three independent shRNA clones and two independent Ctr
clones.
Small interfering RNA, plasmids and constructs
The following small interfering RNA were used: siCTNNB1 (5′-AGCUGA
UAUUGAUGGACAG-3′); siLEF1 (5′-CUACAGGAAUCUGCAUCAG-3′); siAFF3-1
(5′-AGAUGACCUUAAGCUAAGC-3′); siAFF3-2 (5′-UAAGGACUCUCAGCUU
GUA-3′); si-FAM19A4 (5′-GGATGAGAGTCTGTGCTAA-3′); siISM1 (5′-AUA
UCCAGGUCACCAUAGA-3′); siACPL2 (5′-GAAUGGAAUGAGUAGCAAG-3′);
siAXIN2 (5′-UCAAGAAGCAGCAGAUUGA); siNKD1 (5′-GGAUGUGGCACA
UAUAUAC-3′); siCtr (5′-AGCUGAUAUUGAUGGACAG-3′). The AFF3-Flag-
tagged vector from origene (RC221621, Origene, Rockville, MD, USA) was
used to overexpress AFF3. As a Wnt/β-catenin pathway reporter construct-
driving expression of luciferase gene the Top plasmid was used, which
contains two copies of the β-catenin/TCF-binding sites, whereas the Fop
plasmid contains two mutated copies of the β-catenin/TCF-binding sites.
Two copies of the putative AFF3 WRE (wild type or mutant) were tandemly
inserted in the XhoI site of a pGL3Tk reporter plasmid, where luciferase
expression is driven by the minimal Tk promoter. Double-stranded
oligonucleotides with 5′ and 3′ XhoI overhangs were ligated in the
open pGL3Tk vector. 2xWT-F, 5′-tcgaAGGAACAAAGGGGAGAGGAACAAA
GGGGAG-3′; 2xWT-R, 5′-tcgaCTCCCCTTTGTTCCTCTCCCCTTTGTTCCT-3′;
2xMut-F, 5′-tcgaAGGGCCAAAGGGGAGAGGGCCAAAGGGGAG-3′; 2xMut-R,
5′-tcgaCTCCCCTTTGGCCCTCTCCCCTTTGGCCCT-3′. Inserted copy number
was veriﬁed by DNA sequencing of the inserts. Rous sarcoma virus (RSV)-
Renilla (Promega, Charbonnieres, France) was used as a control of
transfection efﬁciencies. Cell tranfection was performed using effecten
(Qiagen 301427). Fireﬂy and Renilla luciferase activities were sequentially
measured with the Dual Luciferase Reporter Assay System (Promega) and
results are expressed as ﬁreﬂy luciferase activity normalized to Renilla
luciferase activity of the same sample.
RNA extraction, RT-qPCR and PCR experiments
RNA extractions from cell lines were performed using Promega kit (Z6012).
Reverse transcription of RNA were performed using High-capacity cDNA
reverse transcription kit (Applied biosystems, Foster City, CA, USA
4368813). The qPCR were performed using the light cycler 480 SYBR
green (Roche, Meylan, France, 04887352001). The PCR conditions for all
target genes were: activation at 95 °C for 5 min followed by 45 cycles of
95 °C for 5 s, annealing at 60 °C for 5 s and 72 °C for 1 s/25 bases with the
primer pairs (forward and reverse) described below: CTNNB1: (5′-
CATTACAACTCTCCACAACC-3′ and 5′-CAGATAGCACCTTCAGCAC-3′, 281
bp); LEF1 (5′-CAGTCATCCCGAAGAGGAAG-3′ and 5′-GCTCCTGAGAGGTTT
GTGCT-3′, 122 bp); AFF3 (5′-ACTCAACAGGATGATGGCAC-3′ and TGCCTAAA
GTGTTCTGGATC-3′, 109 bp); FAM19A4 (5′-TCGCACTGGCTCTTTCTAGC-3′
and 5′-ACCTCACAGGTCCCTTGCTT-3′, 119 bp); ISM1 (5′-CCCCAGATCCTTT
CTCCTTG-3′ and 5′-GTCGACCACCTCTATGGTGA-3′, 103 bp); ACPL2 (5′-
TGACTGCACTCTGGTGGCTA-3′ and 5′-AGGAGTTCAAGGGGCTTTCG-3′, 110
bp); AXIN2 (5′-AGTGTGAGGTCCACGGAAAC-3′ and 5′-CTTCACACTGCGAT
GCATTT-3′, 250 bp); NKD1 (5′-GACAACAACGGCAAGGTCAC-3′ and 5′-
GATGTTGGGGAGTGGTTGAC-3′, 95 bp); PPIA (CYCLO) (5′-ATGGCACTGGT
GGCAAGTCC-3′ and 5′-TTGCCATTCCTGGACCCAAA-3′, 241 bp). The AFF3
variant mRNAs produced were analyzed by producing complementary
DNA from total mRNA from H295R cells, then PCR using oligonucleotides
(AFF3-iso-F, 5′-AATGGGACCTCGAGTCACTG-3′ and AFF3-iso-R, 5′-GGAGA
GTTCATCCCCCTTGT-3′) corresponding to sequences in exon 3 and exon 5,
followed by agarose gel electrophoresis
Protein extraction, immunoprecipitation experiments and
ﬂuorescence immunostaining
H295R cells were washed with cold phosphate-buffered saline (PBS) once
and lysed in a low-salt lysis buffer (20mM Tris HCl (pH 7.4), 0,5% NP40,
20mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA) (pH 7.8))
containing proteinase and phosphatase inhibitors (Roche) for 5 min at
4 °C. After centrifugation at 5000 g for 5 min, the supernatant was removed
(cytoplasmic extract). The nuclear buffer (50mM Tris HCl (pH 7.4), 1% NP40;
400mM NaCl; 1 mM EDTA (pH 7.8)) containing proteinase and phosphatase
inhibitors (Roche) was added to the pellet. Then samples were vortexed
15 s every 10min for a total of 30 min at 4 °C. After centrifugation at
16000 g for 5 min, the balance buffer (50mM Tris HCl (pH 7.4), 1% NP40,
1 mM EDTA) containing proteinase and phosphatase inhibitors (Roche) was
added to the supernatant to make the ﬁnal NaCl concentration 150mM
(nuclear extract). Flag immunoprecipitation: the nuclear extract was
incubated with anti-Flag M2 afﬁnity gel (Sigma A2220) overnight at
4 °C with gentle rotation. The afﬁnity gel were spun down and washed
three times with wash buffer (50 mM Tris HCl (pH 7.4), 1% NP40, 150mM
NaCl, EDTA 1mM (pH 7.8)) containing proteinase and phosphatase
inhibitors (Roche). The elution was made with the peptide 3X Flag (sigma
F4799) at 4 °C for 30min without agitation. CDK9 immunoprecipitation: the
lysate was then incubated with antibodies and protein A coupled magnetic
sepharose beads (GE healthcare 28-9537-63 AA, Velizy-Villacoublay,
France) overnight at 4 °C with gentle rotation. The beads were washed
three times with wash buffer (50 mM Tris HCl (pH 7.4), 1% NP40, 150mM
NaCl, EDTA 1mM (pH 7.8)) containing proteinase and phosphatase
inhibitors (Roche) before boiling at 70 °C in 2% of sodium dodecyl
sulfate-loading buffer for 10min. Fluorescence immunostaining: H295R
cells were washed with cold PBS once and were permeabilized using a
solution of PBS with 0.5% Triton for 10min. The cells were washed with
PBS for three times before incubated with 10% normal goat serum
blocking solution (Invitrogen 50-062Z) at room temperature for 1 h. The
cells were then incubated with primary antibodies overnight at 4 °C. After
three washes with PBS, secondary ﬂuorescent antibodies were added to
the cells for 1 h at room temperature. The nuclei were stained with 4′,6-
diamidino-2-phenylindole and after mounting with Fluoromount G (DAKO,
Les Ulis, France), images were taken with a ﬂuorescence microscope (Zeiss
Axiovert 200M). The following antibodies were used: Anti-cleaved
Caspase3 (9661) and anti-LaminA/C (2032) (Cell Signaling, Saint Quentin
Yvelines, France), Anti-β-ACTIN (A-2066, Sigma-Aldrich), Anti-AFF3 (ARP
34737-P050, Aviva, San Diego, CA, USA), Anti-Flag (F1804) and anti-Sc35
(s4045) (Sigma-Aldrich), Anti-CDK9 (ab 38840) and anti-Cyclin T1 (ab 2098)
(Abcam, Paris, France), Anti-b-Tubulin (sc5274) and normal rabbit IgG
(sc2027) (Santa Cruz, Dallas, TX, USA), Alexa Fluor 488 Anti-mouse IgG
(A11001), Alexa Fluor 488 Anti-rabbit IgG (A11008), Alexa Fluor 647 Anti-
rabbit IgG (A21244), Alexa Fluor 647 Anti-mouse IgG (A21235) (Life
technologies, Saint Aubin, France).
Apoptosis, cell proliferation and colony-formation assay
Apoptosis was analyzed by western blot testing of the amounts of cleaved
caspase-3 and by Caspase-Glo 3/7 Assay (Promega G8091). Proliferation
was measured with the MTT assay (CellTiter 96 Non-Radioactive Cell
Proliferation Assay, Promega). For colony-formation assays, cells from each
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clone were seeded at low density in individual wells of a standard six-well
plate and grown for 30 days in normal serum medium. Colonies were
visualized by crystal-violet staining.
Correlation, expression and statistical analysis
Pearson's r correlation test was used to evaluate the correlation between
gene expression and AXIN2 expression in two, previously described,
independent cohorts of ACC: Cohort 18 included 47 ACC and four NA
(Gene Expression Omnibus data set GSE49280 and ArrayExpress data set
E-TABM-311); and Cohort 2,10 33 ACC and 10 NA (Gene Expression
Omnibus data set GSE33371). All samples were normalized in batches,
independently for each chip type using the RMA algorithm (Bioconductor
affy package), and probe set intensities were then averaged per gene
symbol. Both ﬁnal matrices were row-centered using the NA median.
Differential expression was measured with moderated t-test (limma R
package) and survival curves were obtained by the Kaplan–Meier method.
Differences in survival were assessed with the log-rank test. Gene
expression proﬁles for three H295R/TR/shβ and one control clones with
and without doxycycline treatment were analyzed using Affymetrix Human
Gene 1.0 ST arrays (ArrayExpress data set E-MTAB-3330) and with the
moderated paired t-test (limma R package). All P-values were adjusted
using the Benjamini–Hochberg correction method. All in vitro data
reported with statistical analyses represent means from at least three
experiments. The error bars indicate the s.d. Control conditions were set as
one and data were analyzed by one way analysis of variance followed by
Fisher's LSD post hoc test. Gene set enrichment analysis48 were performed
with several data sets from breast cancers (ArrayExpress data set
E-MTAB-365; Gene Expression Omnibus (GEO) data sets GSE6532,
GSE4922 and GSE1456; and The Cancer Genome Atlas breast carcinoma
data set) and with a data set with inhibition of CDK9 by Flavopiridol.40
Signiﬁcance was set at Po0.05 (represented by * in ﬁgures); Po0.01 (**)
and Po0.001 (***). Analyses were performed using R 3.0.3 with custom
scripts, which can be provided on request.
RNA-seq library preparation and analysis
Total RNA from H295R cells was extracted, and complementary DNA library
was created using Epicentre ScriptSeq strand-speciﬁc after a RNA depletion
optimized with the Ribo-Zero kit (Epicentre, Madison, WI, USA). A paired-
end 10- bp sequencing was performed on a HiSeq 1500 device (Illumina,
San Diego, CA, USA). Reads were mapped to the UCSC (University of
California, Santa Cruz) reference transcripts from hg19 genome using
RSEM (RNA-Seq by Expectation Maximization) and the Bowtie alignment
software. Wiggle ﬁles in genomic coordinate were generated for
visualization.
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